Given that EGFR-TKI therapy confers a survival benefit in some patients with colon, pancreatic, or head and neck tumors that are WT for EGFR, the amount of activated EGFR may be an important marker for the response to TKI therapy in such tumors. Here, EGFR is linked to head and neck neoplasm.